Antitumor activity of doxorubicin in combination with docetaxel against human breast cancer xenografts

Tomohisa Egawa, Tetsuro Kubota, Akihiko Suto, Yoshihide Otani, Toshiharu Furukawa, Yoshiro Saikawa, Masahiko Watanabe, Koichiro Kumai, Masaki Kitajima

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In this study we assessed the inyivo antitumor activity of combined docetaxel (DOCE) and doxorubicin (DXR) treatment using 2 human breast carcinoma cell xenografts (R-27 and MX-1) in the nude mouse model. The transplanted tumors were allowed to reach exponential growth, whereupon 10 or 40 mg DOCE per kg alone (ip), 8 mg DXR per kg alone (iv), or 10 mg/kg DOCE (ip) and 8 mg/kg of DXR (iv), in the sequence of DOCE followed by DXR, were administered. The in vivo antitumor activity of combined DOCE and DXR was synergistic against R-27 and additive against MX-1. P-gfycoprotein (P-gp) was detected immunohistochemically, and was highly expressed in R-27, but not in MX-1. In conclusion, DOCE may increase the antitumor activity of DXR against P-gp-positive breast cancer xenografts, such that the DOCE and DXR combination may be a useful treatment in clinical breast cancer.

Original languageEnglish
Pages (from-to)23-28
Number of pages6
JournalIn Vivo
Volume17
Issue number1
Publication statusPublished - 2003 Jan

Fingerprint

docetaxel
Heterografts
Doxorubicin
Breast Neoplasms
Nude Mice
Tumors

Keywords

  • Breast cancer
  • Combination therapy
  • Docetaxel
  • Doxorubicin
  • In vivo
  • P-glycoprotein
  • Synergism

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Egawa, T., Kubota, T., Suto, A., Otani, Y., Furukawa, T., Saikawa, Y., ... Kitajima, M. (2003). Antitumor activity of doxorubicin in combination with docetaxel against human breast cancer xenografts. In Vivo, 17(1), 23-28.

Antitumor activity of doxorubicin in combination with docetaxel against human breast cancer xenografts. / Egawa, Tomohisa; Kubota, Tetsuro; Suto, Akihiko; Otani, Yoshihide; Furukawa, Toshiharu; Saikawa, Yoshiro; Watanabe, Masahiko; Kumai, Koichiro; Kitajima, Masaki.

In: In Vivo, Vol. 17, No. 1, 01.2003, p. 23-28.

Research output: Contribution to journalArticle

Egawa, T, Kubota, T, Suto, A, Otani, Y, Furukawa, T, Saikawa, Y, Watanabe, M, Kumai, K & Kitajima, M 2003, 'Antitumor activity of doxorubicin in combination with docetaxel against human breast cancer xenografts', In Vivo, vol. 17, no. 1, pp. 23-28.
Egawa, Tomohisa ; Kubota, Tetsuro ; Suto, Akihiko ; Otani, Yoshihide ; Furukawa, Toshiharu ; Saikawa, Yoshiro ; Watanabe, Masahiko ; Kumai, Koichiro ; Kitajima, Masaki. / Antitumor activity of doxorubicin in combination with docetaxel against human breast cancer xenografts. In: In Vivo. 2003 ; Vol. 17, No. 1. pp. 23-28.
@article{b1e8c319f2dc4ac0b471c81f77537a4c,
title = "Antitumor activity of doxorubicin in combination with docetaxel against human breast cancer xenografts",
abstract = "In this study we assessed the inyivo antitumor activity of combined docetaxel (DOCE) and doxorubicin (DXR) treatment using 2 human breast carcinoma cell xenografts (R-27 and MX-1) in the nude mouse model. The transplanted tumors were allowed to reach exponential growth, whereupon 10 or 40 mg DOCE per kg alone (ip), 8 mg DXR per kg alone (iv), or 10 mg/kg DOCE (ip) and 8 mg/kg of DXR (iv), in the sequence of DOCE followed by DXR, were administered. The in vivo antitumor activity of combined DOCE and DXR was synergistic against R-27 and additive against MX-1. P-gfycoprotein (P-gp) was detected immunohistochemically, and was highly expressed in R-27, but not in MX-1. In conclusion, DOCE may increase the antitumor activity of DXR against P-gp-positive breast cancer xenografts, such that the DOCE and DXR combination may be a useful treatment in clinical breast cancer.",
keywords = "Breast cancer, Combination therapy, Docetaxel, Doxorubicin, In vivo, P-glycoprotein, Synergism",
author = "Tomohisa Egawa and Tetsuro Kubota and Akihiko Suto and Yoshihide Otani and Toshiharu Furukawa and Yoshiro Saikawa and Masahiko Watanabe and Koichiro Kumai and Masaki Kitajima",
year = "2003",
month = "1",
language = "English",
volume = "17",
pages = "23--28",
journal = "In Vivo",
issn = "0258-851X",
publisher = "International Institute of Anticancer Research",
number = "1",

}

TY - JOUR

T1 - Antitumor activity of doxorubicin in combination with docetaxel against human breast cancer xenografts

AU - Egawa, Tomohisa

AU - Kubota, Tetsuro

AU - Suto, Akihiko

AU - Otani, Yoshihide

AU - Furukawa, Toshiharu

AU - Saikawa, Yoshiro

AU - Watanabe, Masahiko

AU - Kumai, Koichiro

AU - Kitajima, Masaki

PY - 2003/1

Y1 - 2003/1

N2 - In this study we assessed the inyivo antitumor activity of combined docetaxel (DOCE) and doxorubicin (DXR) treatment using 2 human breast carcinoma cell xenografts (R-27 and MX-1) in the nude mouse model. The transplanted tumors were allowed to reach exponential growth, whereupon 10 or 40 mg DOCE per kg alone (ip), 8 mg DXR per kg alone (iv), or 10 mg/kg DOCE (ip) and 8 mg/kg of DXR (iv), in the sequence of DOCE followed by DXR, were administered. The in vivo antitumor activity of combined DOCE and DXR was synergistic against R-27 and additive against MX-1. P-gfycoprotein (P-gp) was detected immunohistochemically, and was highly expressed in R-27, but not in MX-1. In conclusion, DOCE may increase the antitumor activity of DXR against P-gp-positive breast cancer xenografts, such that the DOCE and DXR combination may be a useful treatment in clinical breast cancer.

AB - In this study we assessed the inyivo antitumor activity of combined docetaxel (DOCE) and doxorubicin (DXR) treatment using 2 human breast carcinoma cell xenografts (R-27 and MX-1) in the nude mouse model. The transplanted tumors were allowed to reach exponential growth, whereupon 10 or 40 mg DOCE per kg alone (ip), 8 mg DXR per kg alone (iv), or 10 mg/kg DOCE (ip) and 8 mg/kg of DXR (iv), in the sequence of DOCE followed by DXR, were administered. The in vivo antitumor activity of combined DOCE and DXR was synergistic against R-27 and additive against MX-1. P-gfycoprotein (P-gp) was detected immunohistochemically, and was highly expressed in R-27, but not in MX-1. In conclusion, DOCE may increase the antitumor activity of DXR against P-gp-positive breast cancer xenografts, such that the DOCE and DXR combination may be a useful treatment in clinical breast cancer.

KW - Breast cancer

KW - Combination therapy

KW - Docetaxel

KW - Doxorubicin

KW - In vivo

KW - P-glycoprotein

KW - Synergism

UR - http://www.scopus.com/inward/record.url?scp=0037241547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037241547&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 23

EP - 28

JO - In Vivo

JF - In Vivo

SN - 0258-851X

IS - 1

ER -